Subdued Q3 for Ranbaxy; investors jittery about Wockhardt
This article was originally published in Scrip
Executive Summary
Weighed down by uncertainties following regulatory action concerning good manufacturing practice (GMP) deviations at their Indian sites, Ranbaxy Laboratories and Wockhardt continue to feel the heat on Indian bourses ahead of their quarterly results later this month.